Cerenome (PSTV) Research & Development (2011 - 2026)
Plus Therapeutics (PSTV) posted quarterly Research & Development of $2.9 million for Q1 2026, up 63.15% year-over-year from $1.8 million in Q1 2025, and down 2.58% quarter-over-quarter from $2.9 million in Q4 2025.
Cerenome (PSTV) Research & Development (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Research & Development for 16 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 63.15% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $9.5 million (down 0.89% YoY), while the FY2025 annual figure was $8.4 million, down 20.8% from the prior year.
- Research & Development slipped to $2.9 million in Q1 2026 per PSTV's latest filing, from $2.9 million in the prior quarter.
- Across five years, Research & Development topped out at $3.0 million in Q1 2023 and bottomed at $75000.0 in Q4 2023.
- Historically, Research & Development has averaged $2.3 million across 5 years, with a median of $2.5 million in 2023.
- Annual changes were most pronounced in 2023 — Research & Development plunged 96.49% — and 2024, when it surged 2814.67%.
- Plus Therapeutics' Research & Development stood at $2.1 million in 2022, then slumped by 96.49% to $75000.0 in 2023, then soared by 2814.67% to $2.2 million in 2024, then jumped by 34.54% to $2.9 million in 2025, then declined by 2.58% to $2.9 million in 2026.
- Business Quant data shows PSTV's Research & Development at $2.9 million in Q1 2026, $2.9 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 4.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 2.94 Mn |
| Sep 30, 2025 | 2.44 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Dec 31, 2024 | 2.19 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 2.77 Mn |
| Mar 31, 2024 | 2.76 Mn |
| Dec 31, 2023 | 75,000.00 |
| Sep 30, 2023 | 2.49 Mn |
| Jun 30, 2023 | 1.42 Mn |
| Mar 31, 2023 | 2.98 Mn |
| Dec 31, 2022 | 2.14 Mn |
| Sep 30, 2022 | 2.95 Mn |
| Jun 30, 2022 | 2.83 Mn |
| Mar 31, 2022 | 1.79 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | 1.49 Mn |
| Jun 30, 2021 | 1.11 Mn |